Tisdag 15 Juli | 22:38:22 Europe / Stockholm

Kalender

Est. tid*
2024-02-29 - Bokslutskommuniké 2023
2023-11-23 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-30 - Årsstämma
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning RLS 0.00 SEK
2023-02-28 - Bokslutskommuniké 2022
2023-02-09 - Extra Bolagsstämma 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning RLS 0.00 SEK
2022-05-19 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-07-16 - Kvartalsrapport 2021-Q2
2021-06-17 - Årsstämma
2021-05-27 - X-dag ordinarie utdelning RLS 0.00 SEK
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-10 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning RLS 0.00 SEK
2020-05-26 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-19 - Extra Bolagsstämma 2019
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning RLS 0.00 SEK
2019-05-29 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-30 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-06-14 - X-dag ordinarie utdelning RLS 0.00 SEK
2018-06-13 - Årsstämma
2018-05-31 - Kvartalsrapport 2018-Q1
2018-02-28 - Bokslutskommuniké 2017
2017-11-28 - Kvartalsrapport 2017-Q3
2017-11-15 - Extra Bolagsstämma 2017
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-09 - X-dag ordinarie utdelning RLS 0.00 SEK
2017-06-08 - Årsstämma
2017-05-31 - Kvartalsrapport 2017-Q1
2017-02-20 - Bokslutskommuniké 2016
2016-11-30 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2
2016-06-01 - X-dag ordinarie utdelning RLS 0.00 SEK
2016-05-31 - Årsstämma
2016-05-31 - Kvartalsrapport 2016-Q1
2016-02-29 - Bokslutskommuniké 2015
2016-01-21 - Extra Bolagsstämma 2016
2015-11-30 - Kvartalsrapport 2015-Q3
2015-08-31 - Kvartalsrapport 2015-Q2
2015-06-12 - X-dag ordinarie utdelning RLS 0.00 SEK
2015-06-11 - Årsstämma
2015-05-28 - Kvartalsrapport 2015-Q1
2015-02-27 - Bokslutskommuniké 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-09-12 - Extra Bolagsstämma 2014
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-10 - X-dag ordinarie utdelning RLS 0.00 SEK
2014-06-09 - Årsstämma
2014-05-23 - Kvartalsrapport 2014-Q1
2014-03-05 - Bokslutskommuniké 2013
2013-11-29 - Kvartalsrapport 2013-Q3
2013-09-04 - Kvartalsrapport 2013-Q2
2013-05-31 - Kvartalsrapport 2013-Q1
2013-05-08 - Split RLS 10:1
2013-04-11 - X-dag ordinarie utdelning RLS 0.00 SEK
2013-04-10 - Årsstämma
2013-03-05 - Bokslutskommuniké 2012
2012-11-26 - Kvartalsrapport 2012-Q3
2012-08-31 - Kvartalsrapport 2012-Q2
2012-06-12 - X-dag ordinarie utdelning RLS 0.00 SEK
2012-06-11 - Årsstämma

Beskrivning

LandSverige
SektorHälsovård
IndustriMedicinteknik
RLS Global är verksamma inom bioteknik. Bolaget utvecklar biokemiska produkter och metoder för behandling av förekommande sår hos patienter. Bolagets produkter angriper skadad vävnad via den egenutvecklade teknologin som baseras på hypoklorit. Idag bedrivs forskning och utveckling inom vävnadsbaserad teknik. Bolaget har sitt huvudkontor i Göteborg.
2022-01-12 08:00:00

RLS Global, a medical healthcare company based in Sweden, and ConvaTec, one of the world's leading advanced wound care companies, have made continued progress with the distribution and commercialisation of ChloraSolv[®], a ground-breaking gentle wound debrider, in Europe.

After intensive market preparation and work with specialist wound experts in the Netherlands, ChloraSolv[®] gel was listed on January 1, 2022 in the Z- index and received a positive recommendation for reimbursement from Zorginstituut Nederland (ZN).

Chlorasolv[®] is already available in other European markets such as the Nordic countries.

Karin Fischer, CEO, RLS Global, said:
"I am very pleased with the registration and positive reimbursement recommendation achieved in the Netherlands. Together with ConvaTec we are focused on accelerating the activities to achieve reimbursement across key European markets".

Sandrine Letellier, VP Global Marketing for ConvaTec Advanced Wound Care, said:
"At ConvaTec we're focused on pioneering trusted medical solutions to improve the lives we touch. Effective debridement is a key step within our Wound Hygiene[TM] Protocol of Care and ChloraSolv[®] brings a new gentle yet effective solution for the management of diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). We shall continue to invest in generating robust clinical and health economic data to illustrate the value we feel the product brings to patients".

ChloraSolv[®], manufactured by RLS Global, is a CE marked wound bed preparation gel intended for cleansing and debridement of the wound[1]. Without damaging the healthy tissue, ChloraSolv[®] ensures fast and easy debridement by softening and making it easy to mechanically remove devitalized tissue, pus and other biological debris that prevents the wound from healing[2,3].

1. ChloraSolv® instructions for use. (https://chlorasolvacademy.se/wp-content/uploads/2021/09/IFU-ChloraSolv-ML-version-2021-09-06.pdf)
2. Berqvist K, Almhöjd U, Herrmann I, Eliasson B. The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial. Clinical Diabetes and Endocrinology; 2016 2:6
3. Eliasson B, Fagerdahl A, Jönsson A, Apelqvist J. Debriding effect of amino acid-buffered hypochlorite on hard-to-heal wounds covered by devitalised tissue: pilot study. Journal of Wound Care; 2021 30:6;

TRADING PLACE AND CERTIFIED ADVISER
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se.During the period 2012-2017, the company was listed on Aktietorget.